Trials / Conditions / Carcinoid Syndrome

Carcinoid Syndrome

26 registered clinical trials studyying Carcinoid Syndrome — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	CardioNETPOL National Registry of Carcinoid Heart Disease NCT07450287	National Institute of Cardiology, Warsaw, Poland	—
Recruiting	Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen NCT07087054	Crinetics Pharmaceuticals Inc.	Phase 3
Recruiting	Fibrosis in Chronic and Delayed Myocardial Infarction NCT05756608	University of Edinburgh	—
Completed	Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome NCT05361668	Crinetics Pharmaceuticals Inc.	Phase 2
Active Not Recruiting	Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease NCT05064514	Queen Mary University of London	N/A
Withdrawn	Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndro NCT04713202	Chandrikha Chandrasekhara	Phase 2
Withdrawn	Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carci NCT04776876	M.D. Anderson Cancer Center	Phase 2
Unknown	Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy NCT04039516	King's College Hospital NHS Trust	Phase 2
Terminated	Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel NCT04073017	Vanderbilt-Ingram Cancer Center	N/A
Completed	Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs NCT03722511	Lowell Anthony, MD	Phase 2
Completed	AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm NCT03453489	Barbara Ann Karmanos Cancer Institute	Phase 2
Completed	Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO NCT03223428	TerSera Therapeutics LLC	—
Terminated	Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation NCT04140409	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Phase 4
Active Not Recruiting	An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors NCT04993261	M.D. Anderson Cancer Center	EARLY_Phase 1
Completed	Telotristat Etiprate for Carcinoid Syndrome Therapy NCT02063659	Lexicon Pharmaceuticals	Phase 3
Completed	Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms NCT02026063	Lexicon Pharmaceuticals	Phase 3
Completed	An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Mal NCT01932528	Lexicon Pharmaceuticals	Phase 1
Withdrawn	Study of Panitumumab in the Treatment of Carcinoid Syndrome NCT01172717	Boston Medical Center	Phase 2
Completed	TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) NCT01677910	Lexicon Pharmaceuticals	Phase 3
Completed	Effects of Serotonin Excess on Bone in Carcinoid Syndrome NCT01430871	Sheffield Teaching Hospitals NHS Foundation Trust	—
Completed	A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of NCT01234168	Ipsen	—
Completed	Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome NCT01104415	Lexicon Pharmaceuticals	Phase 2
Terminated	Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome NCT01018953	Ipsen	Phase 2
Terminated	Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome NCT00884715	Endo Pharmaceuticals	Phase 1 / Phase 2
Completed	An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome NCT00774930	Ipsen	Phase 3
Completed	Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stab NCT00853047	Lexicon Pharmaceuticals	Phase 2